secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001213900-23-060254
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity adds Benjamin, Oliver, Vazzano as directors; cures Nasdaq compliance gap
--------------------------------------------------------------------------------

- Director David Roth resigned July 21, 2023 for personal reasons; Board expanded from 5 to 7 seats.
- Appointed Laura Benjamin (OncXerna CEO), Robert Oliver (ex-Otsuka America CEO), Joseph Vazzano (Abeona CFO) as independent directors effective Aug 1, 2023.
- New board: 4 of 6 independent; Audit & Comp committees fully independent; expected to cure Nasdaq independence rules.
- Independent directors receive $50k annual retainer plus committee fees; each gets options for 2,300 shares subject to stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/ea182404-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-060254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer